Leukemia Therapeutics Market - Global
Industry Insights, Trends, Outlook, and
Opportunity Analysis, 2018-2026
Leukemia also known as blood cancer hinders ability of an individual to fight infection. It is
characterized by formation of tumors in blood-forming tissues including bone marrow. Various type
of leukemia include acute lymphoblastic leukemia, acute myeloid leukemia, and chronic
lymphocytic leukemia. Fatigue, weight loss, frequent infections and easy bleeding or bruising are
some of the symptoms of this disease. Treatment of early leukemia include monitoring and severe
leukemia is treated with chemotherapy, followed by radiation and stem-cell transplant. According to
Center for Disease Control and Prevention (CDC), in the U.S. around 45,360 people were
diagnosed with leukemia in 2013, leading to 23,549 fatalities (13,625 men and 9,924 women). The
condition is more prevalent among men than women.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/528
High diagnosis rate in developed economies supporting the leukemia therapeutics market
growth in those regions
According to the Centre for Disease Control (CDC), around 14.1 million people were diagnosed
with cancer in 2012, resulting in around 8.2 million fatalities. Around 19.3 million new cases of
cancer are projected to be diagnosed by 2025. Leukemia cases are projected to be more in the
developed economies such as North America and Europe, owing to genetic mutations caused by